These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 28486001)

  • 1. Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: part II Gram-negative bacteria.
    Abdelraouf K; Linder KE; Nailor MD; Nicolau DP
    Expert Opin Drug Metab Toxicol; 2017 Jul; 13(7):705-714. PubMed ID: 28486001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance.
    Monogue ML; Kuti JL; Nicolau DP
    Expert Rev Clin Pharmacol; 2016; 9(3):459-76. PubMed ID: 26678036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: Part I gram positive bacteria.
    Linder KE; Nicolau DP; Nailor MD
    Expert Opin Drug Metab Toxicol; 2016; 12(3):267-80. PubMed ID: 26751348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review.
    Sumi CD; Heffernan AJ; Lipman J; Roberts JA; Sime FB
    Clin Pharmacokinet; 2019 Nov; 58(11):1407-1443. PubMed ID: 31325141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens.
    Scheetz MH; Hurt KM; Noskin GA; Oliphant CM
    Am J Health Syst Pharm; 2006 Jul; 63(14):1346-60. PubMed ID: 16809756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic/pharmacodynamic target attainment of intravenous β-lactam regimens against Gram-negative bacteria isolated in a Brazilian teaching hospital.
    Furtado GH; Cardinal L; Macedo RS; Silva JO; Medeiros EA; Kuti JL; Nicolau DP
    Rev Soc Bras Med Trop; 2015; 48(5):539-45. PubMed ID: 26516962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections.
    Bassetti M; Pecori D; Cojutti P; Righi E; Pea F
    Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1193-1200. PubMed ID: 28988505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?
    Falagas ME; Mavroudis AD; Vardakas KZ
    Expert Rev Anti Infect Ther; 2016 Aug; 14(8):747-63. PubMed ID: 27400643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Declining susceptibilities of gram-negative bacteria to the fluoroquinolones: effects on pharmacokinetics, pharmacodynamics, and clinical outcomes.
    Labreche MJ; Frei CR
    Am J Health Syst Pharm; 2012 Nov; 69(21):1863-70. PubMed ID: 23111670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of polymyxin resistance in Gram-negative bacteria.
    Olaitan AO; Li J
    Int J Antimicrob Agents; 2016 Dec; 48(6):581-582. PubMed ID: 27939183
    [No Abstract]   [Full Text] [Related]  

  • 11. Combination therapy for carbapenem-resistant Gram-negative bacteria.
    Zavascki AP; Bulitta JB; Landersdorfer CB
    Expert Rev Anti Infect Ther; 2013 Dec; 11(12):1333-53. PubMed ID: 24191943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial resistance and treatment: an unmet clinical safety need.
    Bassetti M; Russo A; Carnelutti A; La Rosa A; Righi E
    Expert Opin Drug Saf; 2018 Jul; 17(7):669-680. PubMed ID: 29897796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colistin: still a lifesaver for the 21st century?
    Karaiskos I; Souli M; Galani I; Giamarellou H
    Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):59-71. PubMed ID: 27573251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to polymyxins: Mechanisms, frequency and treatment options.
    Falagas ME; Rafailidis PI; Matthaiou DK
    Drug Resist Updat; 2010; 13(4-5):132-8. PubMed ID: 20843473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement.
    Chopra I; Schofield C; Everett M; O'Neill A; Miller K; Wilcox M; Frère JM; Dawson M; Czaplewski L; Urleb U; Courvalin P
    Lancet Infect Dis; 2008 Feb; 8(2):133-9. PubMed ID: 18222164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidrug efflux pumps and their role in antibiotic and antiseptic resistance: a pharmacodynamic perspective.
    Alibert S; N'gompaza Diarra J; Hernandez J; Stutzmann A; Fouad M; Boyer G; Pagès JM
    Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):301-309. PubMed ID: 27764576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of infections caused by Gram-negative pathogens: current status on the pharmacokinetics/pharmacodynamics of parenteral and inhaled polymyxins in patients.
    Lin YW; Aye SM; Rao G; Zhou QT; Chan HK; Li J
    Int J Antimicrob Agents; 2020 Dec; 56(6):106199. PubMed ID: 33075510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective.
    Mouton JW; Ambrose PG; Canton R; Drusano GL; Harbarth S; MacGowan A; Theuretzbacher U; Turnidge J
    Drug Resist Updat; 2011 Apr; 14(2):107-17. PubMed ID: 21440486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic optimization of antibiotics for Gram-negative infections.
    Gill CM; Nicolau DP
    Curr Opin Infect Dis; 2019 Dec; 32(6):647-655. PubMed ID: 31567737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region.
    Roberts JA; Kwa A; Montakantikul P; Gomersall C; Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2011 Mar; 37(3):225-9. PubMed ID: 21168997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.